Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.